Australian Federal Court Rules Isolated Genetic Material can be Patented
By The Guardian,
The Guardian
| 09. 04. 2014
The federal court has ruled that a company may patent genetic material that has been extracted from the human body, in a move that may have serious repercussions for the future of medical research in Australia.
Cancer Voices Australia began legal action over patents associated with a gene known as BRCA1 in 2010. Mutated versions of this gene, which women can be born with, have been associated with an increased risk of hereditary breast and ovarian cancers.
“[The patenting of this material] places limits on genetic testing, genetic research and the development of treatments and cures for genetically associated disease,” the Maurice Blackburn lawyer Rebecca Gilsenan said.
“Gene patents are of great concern to the medical research community and to the medical profession. Gene patents stifle innovation.”
In February last year the federal court ruled that genetic material associated with mutated versions of BRCA1, once isolated from the human body, could be patented. Cancer Voices Australia appealed against the decision, but on Friday the full bench of the court upheld the ruling.
The companies involved are US-based Myriad Genetics and...
Related Articles
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
